Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Chandler, Arizona Clinical Trials

A listing of Chandler, Arizona clinical trials actively recruiting patient volunteers.

RESULTS

Found (69) clinical trials

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality ...

Phase

0.0 miles

Learn More »

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.

Phase

0.0 miles

Learn More »

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

This will be a 12-week, randomized, double-blind, placebo-controlled, 4-arm, parallel group, multi-center study to evaluate the safety and efficacy of LGD-6972 in subjects with T2DM inadequately controlled on metformin monotherapy (a stable [≥12 weeks], daily dose of ≥1000mg at randomization). Subjects with T2DM will be treated with one of 3 ...

Phase

2.08 miles

Learn More »

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of the treatment period (Week 12). Secondary endpoints include effects ...

Phase

2.08 miles

Learn More »

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Primary Objectives To evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 To evaluate the safety and tolerability of seladelpar in subjects with NASH Secondary Objectives To evaluate the effect of seladelpar on hepatic fat fraction, as ...

Phase

2.08 miles

Learn More »

A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale

The primary objective of the study is to assess the responsiveness of the Brief Arthritis Stiffness Scale (BASS) for detecting treatment effects of common OTC analgesics and a common prescription analgesic in subjects with knee osteoarthritis.

Phase

2.08 miles

Learn More »

Emricasan a Caspase Inhibitor for Treatment of Subjects With Decompensated NASH Cirrhosis

The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48. All subjects will continue treatment until the last subject in the study reaches 48 weeks in the study. At least 30% of subjects ...

Phase

2.08 miles

Learn More »

Study of ISIS 703802 in Subjects With Hypertriglyceridemia Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS 703802 on glucose and lipid metabolism, and liver fat in subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and ...

Phase

2.08 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Gefapixant (MK-7264) in Women With Endometriosis-Related Pain (MK-7264-034)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of gefapixant (MK-7264) in premenopausal female participants with moderate to severe endometriosis-related pain. The primary hypothesis: gefapixant is superior to placebo in reducing the average daily pelvic pain score (cyclic and non-cyclic) during Treatment Cycle 2.

Phase

2.08 miles

Learn More »

Safety Tolerability and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)

The purpose of this study is to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Phase

2.08 miles

Learn More »